Bone mineral density in lymphangioleiomyomatosis.
ABSTRACT Estrogen deficiency and pulmonary diseases are associated with bone mineral density (BMD) loss. Lymphangioleiomyomatosis (LAM), a disorder affecting women that is characterized by cystic lung lesions, is frequently treated with antiestrogen therapy, i.e., progesterone and/or oophorectomy. Therefore, we evaluated BMD yearly in 211 LAM patients to determine the prevalence of BMD abnormalities, whether antiestrogen therapy decreased BMD, and if treatment with bisphosphonates prevented bone loss. Abnormal BMD was found in 70% of the patients and correlated with severity of lung disease and age. Greater severity of lung disease, menopause, and oophorectomy were associated with greater decline in BMD. After adjusting for differences in initial lung function and BMD, we found similar rates of BMD decline in progesterone-treated (n = 122) and untreated patients (n = 89). After similar adjustments, we found that bisphosphonate-treated patients (n = 98) had lower rates of decline in lumbar spine BMD (-0.004 +/- 0.003 vs. -0.015 +/- 0.003 gm/cm(2), p = 0.036) and T-scores (-0.050 +/- 0.041 vs. -0.191 +/- 0.041, p < 0.001) than untreated patients (n = 113). We conclude that abnormal BMD was frequent in LAM. Progesterone therapy was not associated with changes in BMD; bisphosphonate therapy was associated with lower rates of bone loss. We recommend systematic evaluation of BMD and early treatment with bisphosphonates for patients with LAM.
- SourceAvailable from: ncbi.nlm.nih.gov[Show abstract] [Hide abstract]
ABSTRACT: Lymphangioleiomyomatosis (LAM) is a rare disease characterised by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to progressive cystic destruction of the lung, lymphatic abnormalities and abdominal tumours. It affects predominantly females and can occur sporadically or in patients with tuberous sclerosis complex. This review describes the recent progress in our understanding of the molecular pathogenesis of the disease and LAM cell biology. It also summarises current therapeutic approaches and the most promising areas of research for future therapeutic strategies.European Respiratory Review 03/2011; 20(119):34-44.
- European Respiratory Review 01/2011;
- [Show abstract] [Hide abstract]
ABSTRACT: In addition to its effects on bone metabolism, osteoprotegerin (OPG), a soluble member of the tumor necrosis factor family of receptors, promotes smooth muscle cell proliferation and migration and may act as a survival factor for tumor cells. We hypothesized that these cellular mechanisms of OPG may be involved in the growth and proliferation of lymphangioleiomyomatosis (LAM) cells, abnormal smooth muscle-like cells with mutations in one of the tuberous sclerosis complex tumor-suppressor genes (TSC1/TSC2) that cause LAM, a multisystem disease characterized by cystic lung destruction, lymphatic infiltration, and abdominal tumors. Herein, we show that OPG stimulated proliferation of cells cultured from explanted LAM lungs, and selectively induced migration of LAM cells identified by the loss of heterozygosity for TSC2. Consistent with these observations, cells with TSC2 loss of heterozygosity expressed the OPG receptors, receptor activator of NF-κB ligand, syndecan-1, and syndecan-2. LAM lung nodules showed reactivities to antibodies to tumor necrosis factor-related apoptosis-inducing ligand, receptor activator of NF-κB ligand, syndecan-1, and syndecan-2. LAM lung nodules also produced OPG, as shown by expression of OPG mRNA and colocalization of reactivities to anti-OPG and anti-gp100 (HMB45) antibodies in LAM lung nodules. Serum OPG was significantly higher in LAM patients than in normal volunteers. Based on these data, it appears that OPG may have tumor-promoting roles in the pathogenesis of lymphangioleiomyomatosis, perhaps acting as both autocrine and paracrine factors.American Journal Of Pathology 07/2013; · 4.60 Impact Factor
BONE MINERAL DENSITY IN LYMPHANGIOLEIOMYOMATOSIS (LAM).
Angelo M. Taveira-DaSilva, M.D., Ph.D.1, Mario P. Stylianou, Ph.D.2, Carolyn J. Hedin,
C.R.N.P.1, Olanda Hathaway C.R.N.P.1 , and Joel Moss, M.D., Ph.D.1
Pulmonary-Critical Care Medicine Branch 1 and Office of Biostatistics Research 2,
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Corresponding author: Angelo M. Taveira-DaSilva, M.D., Ph.D.: Pulmonary-Critical
Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of
Health, Building 10, Room 6D05, MSC 1590, Bethesda, MD 20892-1590; Telephone:
301-496-1117; Fax: 301-496-2363; E-mail: firstname.lastname@example.org.
Subject code: 75.
Running Head: Bone mineral density in LAM.
Word count: 3540.
Supported by NHLBI Intramural Research.
AJRCCM Articles in Press. Published on October 1, 2004 as doi:10.1164/rccm.200406-701OC
Copyright (C) 2004 by the American Thoracic Society.
Estrogen deficiency and pulmonary diseases are associated with bone mineral
density (BMD) loss. Lymphangioleiomyomatosis (LAM), a disorder affecting women
that is characterized by cystic lung lesions, is frequently treated with anti-estrogen
therapy, i.e., progesterone and/or oophorectomy. Therefore, we evaluated BMD
yearly in 211 LAM patients to determine the prevalence of BMD abnormalities,
whether anti-estrogen therapy decreased BMD, and if treatment with
bisphosphonates prevented bone loss. Abnormal BMD, found in 70% of the patients,
was correlated with severity of lung disease and age. Greater severity of lung
disease, menopause and oophorectomy were associated with greater decline in
BMD. After adjusting for differences in initial lung function and BMD, we found
similar rates of BMD decline in progesterone-treated (n=122) and untreated patients
(n=89). After similar adjustments we found that bisphosphonate-treated patients
(n=98) had lower rates of decline in lumbar spine BMD (-0.004±0.003 vs. -
0.015±0.003 gm/cm 2, p=0.036) and T-scores (-0.050±0.041 vs. -0.191± 0.041,
p<0.001), than untreated patients (n=113). We conclude that abnormal BMD was
frequent in LAM. Progesterone therapy was not associated with changes in BMD;
bisphosphonate therapy was associated with lower rates of bone loss. We
recommend systematic evaluation of BMD and early treatment with bisphosphonates
for patients with LAM.
Word count: 199
Key words: Interstitial lung disease; bone mineral density; lung function; progesterone;
Lymphangioleiomyomatosis (LAM), a disease affecting primarily women, is
characterized by cystic lung lesions, recurrent pneumothorax, chylous effusions,
lymphatic abnormalities, and abdominal tumors, i.e., angiomyolipomas,
lymphangioleiomyomas (1-4). LAM occurs sporadically in patients with no evidence
of genetic disease and in about one third of women with tuberous sclerosis complex
(TSC) (5-7). Generally, the pulmonary manifestations dominate the clinical features
of LAM. The severity of lung disease, as measured by oxygen requirements,
roentgenographic abnormalities, and exercise tolerance, correlates with the severity
of the lung function abnormalities (8,9). These abnormalities, characterized by
airflow obstruction and decreased diffusion capacity (DLCO), may cause respiratory
failure, requiring oxygen therapy and may result in lung transplantation, or death.
The rate of progression of disease however, is variable, and some patients have a
chronic course lasting more than 20 years (8,9).
There is evidence suggesting that LAM may be influenced by hormonal factors.
Indeed, not only does LAM affect primarily women (1-4), but the disease appears to
progress during pregnancy (10,11), or following the administration of estrogens (12-
14). In addition, there is evidence for the co-localization of estrogen and
progesterone receptors in LAM cells (15-18). Consequently, hormonal manipulations
that reduce the production of estrogens, such as treatment with progesterone and/or
oophorectomy, have been employed in the treatment of LAM. Since estrogen
deficiency is a recognized cause of osteoporosis (19), we hypothesized that anti-
estrogen therapy in the presence of lung disease could adversely affect bone
mineral density (BMD) in patients with LAM. To test this hypothesis, we measured
BMD yearly in a large group of women with LAM followed for more than three years.
The aims of our study were three fold: 1) to determine the prevalence and factors
associated with BMD abnormalities; 2) to determine whether treatment with
progesterone is associated with an accelerated loss of bone; and 3) to determine
whether treatment with bisphosphonates is associated with lower rates of decline in
Some of the results of this study have been previously reported in the form of an
MATERIAL AND METHODS Word count: 716
Study Population. The study population consisted of 305 patients with LAM referred to NIH
since 1995 for participation in a natural history longitudinal study (NHLBI Protocol 95-H-0186)
approved by the Institutional Review Board of the National Heart, Lung, and Blood Institute. In
addition to self-referral or referral through individual physicians, subjects were informed of the
study by the LAM Foundation and the Tuberous Sclerosis Alliance. All subjects gave informed
consent before enrollment. Sixty-three patients who had only one set of BMD studies and 31
patients who had lung transplantation were excluded. Complete data for analysis were
available from 211 patients. The diagnosis of LAM was made by lung or intra-abdominal tissue
biopsy, or by clinical and roentgenographic data (9). Patients were considered to have reached
menopause when menopause had occurred naturally (low estradiol levels and elevated follicle-
stimulating hormone levels) or was surgically induced (bilateral oophorectomy). A patient was
defined as postmenopausal if hormonal levels, as well as history, were consistent with a
menopausal state for most of the duration of the study. The decision to initiate progesterone
therapy and the choice of route of administration were made, independently, by the patients’
physicians and was not part of the NHLBI protocol. The majority of the progesterone-treated
patients were on this therapy for the duration of the study. Patients with osteoporosis were
advised to take bisphosphonates but the final decision for implementation of this therapy was
left up to the patient and her family physician. However, in the majority of the patients,
bisphosphonate therapy was started after the first abnormal BMD test, and continued
thereafter. Hormonal replacement therapy was discontinued after the first visit. Compliance with